Besides bisphosphonates, which medication is most commonly implicated in causing medication-related osteonecrosis of the jaw (MRONJ)?

Denosumab, a monoclonal antibody that inhibits RANKL (and thus osteoclast activity, similar in effect to bisphosphonates but via a different mechanism), is the next most commonly implicated antiresorptive drug in MRONJ. Antiangiogenic agents (e.g., bevacizumab, sunitinib) and mTOR inhibitors are also recognized but less common causes.